de Araújo Rafael B, Azevedo Breno M S, Andrade Thais S, Abalem Maria F, Monteiro Mário L R, Carricondo Pedro C
1Division of Ophthalmology, Hospital Universitário Onofre Lopes, Universidade Federal do Rio Grande do Norte, Rua Mipibu, 741 apt 1402A, Natal, RN 59014-480 Brazil.
2Division of Ophthalmology, Hospital das Clínicas HCFMUSP, Universidade de Sao Paulo, Rua Dr. Ovídio Pires de Campos, 225, 05403-010 São Paulo, SP Brazil.
Int J Retina Vitreous. 2018 Oct 17;4:38. doi: 10.1186/s40942-018-0142-y. eCollection 2018.
Pupil dilation and mydriasis maintenance throughout vitreoretinal surgeries are important to allow satisfactory fundus visualization and reduce risk of complications. The purpose of this study is to evaluate the role of subconjunctival epinephrine 0.1% injection in mydriasis maintenance during vitrectomy.
Ninety-nine consecutive patients undergoing vitrectomy were enrolled. All subjects were preoperatively dilated with tropicamide 1%. Each patient was randomly allocated either in the epinephrine or placebo group. In epinephrine group, patients were submitted to a 0.2 cc subconjunctival injection of a 0.1% epinephrine solution just before first incisions. In placebo group, the same procedure was performed with 0.2 cc of saline 0.9%. Horizontal pupil diameter was measured with calipers before and in the end of the procedure.
Patients in the epinephrine group showed a significantly larger mean pupil diameter in the end of the surgery compared to placebo. There was a significant increase of mean pupil diameter from the beginning to the end of the surgery in such patients. Blood pressure was significantly higher in the epinephrine group than in placebo group. No other adverse effects were noted.
Subconjunctival epinephrine is effective for maintaining and increasing pupil size during vitrectomy, compared to placebo. Caution should be taken regarding intraoperative blood pressure levels.
RBR; RBR-3qzhvg; Registered 8 May 2018-Retrospectively registered, http://www.ensaiosclinicos.gov.br/rg/RBR-3qzhvg/.
在玻璃体视网膜手术中,瞳孔扩张及维持散大对于获得满意的眼底视野及降低并发症风险至关重要。本研究旨在评估结膜下注射0.1%肾上腺素在玻璃体切除术中维持瞳孔散大的作用。
纳入99例连续接受玻璃体切除术的患者。所有受试者术前均用1%托吡卡胺散瞳。每位患者随机分为肾上腺素组或安慰剂组。肾上腺素组患者在首次切口前接受结膜下注射0.2cc 0.1%肾上腺素溶液。安慰剂组采用相同操作,注射0.2cc 0.9%生理盐水。手术开始前及结束时用卡尺测量水平瞳孔直径。
与安慰剂组相比,肾上腺素组患者在手术结束时平均瞳孔直径明显更大。该组患者手术开始至结束时平均瞳孔直径显著增加。肾上腺素组血压明显高于安慰剂组。未观察到其他不良反应。
与安慰剂相比,结膜下注射肾上腺素在玻璃体切除术中对维持和增大瞳孔大小有效。术中应注意血压水平。
RBR;RBR-3qzhvg;2018年5月8日注册——回顾性注册,http://www.ensaiosclinicos.gov.br/rg/RBR-3qzhvg/ 。